News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharmacyclics, Inc. (PCYC) Snags $50 Million As Cancer Drug Moves Toward European Approval


11/21/2013 8:06:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A step toward European approval of the blood cancer drug Imbruvica will net Pharmacyclics Inc. a $50 million payment from partner Johnson & Johnson. The European Medicines Agency on Tuesday told Janssen-Cilag NV, a subsidiary of Johnson & Johnson (NYSE: JNJ), that its application seeking approval of the drug is valid. That triggers the milestone payment to Sunnyvale-based Pharmacyclics (NASDAQ: PCYC).

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES